Due to its ability to target breast cancer stem-like cells and bulk MDA-MB-231 (triple-negative, basal-like) and SUM-159 (triple-negative, mesenchymal) breast cancer cells from ALDH+ and ALDH+/CD44+/CD24− tumor initiating subpopulation, LLL12 is a therapeutic candidate. The gene discussed is CD44; the disease is breast cancer.